Sign In
Buy KRYS
$301.82
+8.61 (+2.94%)
At Close: Jun 03, 2026
Why Is Krystal Biotech (KRYS) Up 3% Since Last Earnings Report?
12:30pm, Wednesday, 03'rd Jun 2026
Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?
Here's Why Krystal Biotech, Inc. (KRYS) is a Strong Momentum Stock
10:51am, Tuesday, 26'th May 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
NORWOOD, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, t
Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
08:00am, Monday, 18'th May 2026
VYJUVEK approved for the treatment of DEB from birth with flexible administration options similar to those already granted in the United States, European Union, and Japan VYJUVEK is the first geneti
Krystal Biotech, Inc. (KRYS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
04:40pm, Wednesday, 13'th May 2026
Krystal Biotech, Inc. (KRYS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
This Profitable Biotech Stealthily Climbs Into A Buy Zone
02:15pm, Monday, 11'th May 2026
This genetic disorder treatment developer's stock hit a buy point after the biotech's first-quarter earnings report last week.
Krystal Biotech: Vyjuvek Is Not The Primary Asset
06:10am, Sunday, 10'th May 2026
Krystal Biotech leverages its HSV-1 gene delivery platform, with VYJUVEK generating strong cash flow and 95% gross margins since FDA approval. KRYS is rated Buy, justified by a robust pipeline—espec
Krystal Biotech to Present at BofA Securities 2026 Health Care Conference
08:00am, Thursday, 07'th May 2026
PITTSBURGH, May 07, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the BofA Securities 2026 Health Care Conferen
Krystal Biotech: A Q1 Earnings Beat With Multiple Catalysts In 2026 And 2027
08:49am, Wednesday, 06'th May 2026
Krystal Biotech delivered strong Q1 2026 results, with Vyjuvek sales up 32% YoY to $116.4M and gross margin expanding to 95%. KRYS's robust balance sheet ($823M cash and negligible debt) and disciplin
Krystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results
02:19pm, Tuesday, 05'th May 2026
Krystal Biotech Inc (NASDAQ:KRYS) reported upbeat earnings for the first quarter on Monday.
Krystal Biotech Q1 Earnings & Sales Beat Estimates, Pipeline in Focus
02:00pm, Tuesday, 05'th May 2026
KRYS shares jump after a Q1 beat as Vyjuvek fuels 32% revenue growth, strong uptake and global expansion, with pipeline catalysts lined up through 2026.
Krystal Biotech, Inc. (KRYS) Q1 2026 Earnings Call Transcript
01:43pm, Monday, 04'th May 2026
Krystal Biotech, Inc. (KRYS) Q1 2026 Earnings Call Transcript
Krystal Biotech, Inc. (KRYS) Tops Q1 Earnings and Revenue Estimates
09:15am, Monday, 04'th May 2026
Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $1.83 per share, beating the Zacks Consensus Estimate of $1.45 per share. This compares to earnings of $1.2 per share a year ago.
Krystal Biotech Announces First Quarter 2026 Financial and Operating Results
07:00am, Monday, 04'th May 2026
$116.4 million in 1Q VYJUVEK global revenue and $846.7 million since launch Enrollment complete in KB803 (corneal abrasions in DEB patients) registrational study On track for KB803 and KB801 (NK) regi
Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates
09:35am, Thursday, 30'th Apr 2026
Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.89. This compares to a loss of $0.82 per share a year ago.
